MAP4K2 and neoplasm: In line with our findings, it has been previously described that, in tumor cells, Lenvatinib directly binds with several components within the MAPK signaling pathway, including MAP4K2, MAP4K5, MAPK14, and MAPKAPK2 [49,50].